"Italy has a historically very important pharmacological production and innovation capacity; it is among the top two to three producers and the top drug exporting country. People always think of food or fashion; actually the first export item for Italy is drugs. These are the skills that lead us to invest in the Italian pharmaceutical manufacturing sector". This is according to Valentino Confalone, Country President of Novartis, announcing investments of 350 million euros in Italy by 2025. "We are working on three innovative technology platforms: the first is cell therapies. The second is mRNAs, which have become famous for anti-Covid vaccines, but which have many other applications, particularly in the cardiovascular area. Finally, there is the whole area of radioligands that act in a very precise and targeted manner, attacking only cancer cells. The first application will be in advanced prostate cancer".